Despite improved safety of food, water, and sanitation and aggressive promotion of noninvasive interventions (e.g., oral rehydration therapy) and prevention strategies (e.g., increased breastfeeding), diarrhea remains a common cause of illness worldwide. It accounts for ≈1.8 million annual deaths in children \<5 years of age ([@R1]). Reduction of this disease will require targeted prevention and treatment strategies against the common agents causing severe diarrhea.

Noroviruses (NoVs) and sapoviruses are genetically and antigenically diverse single-stranded RNA viruses that belong to 2 different genera (*Norovirus* and *Sapovirus)* in the family *Caliciviridae* and are collectively referred to as human caliciviruses ([@R2]). The prototype virus of the NoVs, Norwalk virus, was identified in 1972. However, the inability to cultivate these viruses in routine cell culture and the consequent challenges in developing sensitive nonmolecular diagnostic assays hindered initial efforts to define the epidemiology and assess the impact of disease associated with NoV infection. In the past 15 years, the availability of sensitive molecular diagnostic methods based on reverse transcription--PCR (RT-PCR) has allowed broader examination of the etiologic role of NoVs in epidemic and sporadic gastroenteritis ([@R3],[@R4]).

Since the application of molecular assays, NoVs have been well-documented as the leading cause of epidemic gastroenteritis in all age groups, causing \>90% of nonbacterial and ≈50% of all-cause epidemic gastroenteritis worldwide ([@R5]). Recent studies that used improved diagnostics have demonstrated that NoVs may also fill in the "diagnostic gap" in severe sporadic gastroenteritis among all age groups worldwide ([@R6]). Much of the misconception of NoV as an infrequent cause of severe sporadic diarrhea might also stem from studies undertaken before the mid-1990s that found low rates of NoV infection because available diagnostics such as electron microscopy and antigen detection assays had poor sensitivity. Recent data are emerging that are debunking these misconceptions, suggesting that the impact of NoV disease may be much greater than previously suspected and the disease may be more severe in some populations ([@R4],[@R6]--[@R8]). However, because these novel assays are not typically available outside of reference laboratories, the true global prevalence and potential economic impact of NoV disease remain unrecognized ([@R3]). To further understand the etiologic role of NoVs in sporadic diarrhea, we conducted a systematic review to identify studies that used similar inclusion criteria and molecular assays based on RT-PCR to detect NoVs in fecal specimens from patients with diarrhea.

Methods
=======

We searched MEDLINE, EMBASE, and Google Scholar to identify studies published in English between January 1990 and February 2008. We used the following keywords: *Norwalk*, *norovirus,* *Norwalk-like virus,* *human calicivirus,* *calicivirus,* *NLV,* *small round virus,* and *small round structured virus*. We reviewed all abstracts to identify articles that assessed the prevalence of NoV among sporadic cases of diarrhea. To ensure complete capture of all relevant studies, we cross-referenced all articles from the bibliography of the selected articles. After reviewing each article, we selected studies that met the following inclusion criteria: 1) study duration was [\>]{.ul}1 year, and 2) study used RT-PCR to diagnose caliciviruses (NoV and sapovirus) or NoV in patients with diarrhea. We included studies that tested for caliciviruses, even when they did not differentiate between NoV and sapovirus. For these studies, we multiplied the proportion of caliciviruses detected in each study by the mean proportion of caliciviruses that were NoV among studies that differentiated between NoVs and sapoviruses to yield the estimated NoV prevalence in each study. We excluded studies that did not provide a denominator (i.e., the total number of patients with diarrhea in the study population) or that only conducted molecular analysis using a fraction of the fecal samples ([Technical Appendix 1](#SD1){ref-type="local-data"}). If the authors presented the data again in another study, only 1 study was included. See [Technical Appendix 2](#SD2){ref-type="local-data"}, for a list of all references used in the review but not cited in this article.

We stratified studies into 2 settings: community or clinic-based (mild or moderate diarrhea) and hospital-based including emergency department and inpatients (severe diarrhea). We counted cases in which NoV was detected in the presence of [\>]{.ul}1 other pathogens (i.e., mixed infection) as NoV infection; however, we also present data on mixed infections, when available. Pooled proportions and 95% confidence intervals (CIs) of NoV-positive cases were calculated by using the random effects models (DerSimonnian and Laird method, StatsDirect Ltd, Cheshire, UK). For the studies that included fecal testing on concurrent diarrhea-free controls, the pooled proportions were based on absolute difference in NoV detection rate between cases and controls, thus only including the fraction of cases attributable to NoVs. The Cochran Q statistic and degrees of freedom (df) are presented as a measure of heterogeneity among studies. Analyses were conducted with StatsDirect version 2.5.7 (StatsDirect Ltd).

To calculate the number of outpatient NoV episodes and hospitalizations for children living in industrialized countries (where 23 of 31 studies in our review were conducted), we multiplied the total number of estimated diarrhea episodes in each clinical setting by the pooled proportion attributable to NoV based on the studies we reviewed to yield the number of NoV cases in each setting ([@R9]). No data exist on estimates of total diarrhea episodes in industrialized countries. Thus, we divided the estimates of outpatient and inpatient rotavirus episodes for industrialized countries, provided by Parashar et al. ([@R9]), by the proportion of diarrhea episodes attributable to rotavirus (23% and 42%, respectively) in the United States ([@R10]) and Europe ([@R11]) to yield the annual number of total diarrhea episodes in industrialized countries. To estimate the proportion of outpatient (23%) and inpatient (42%) diarrhea episodes attributable to rotavirus, we assumed the midpoint of the proportion of gastroenteritis visits attributable to rotavirus in the United States (19% and 35%, respectively) and 7 European countries (27% and 50% respectively) for each setting, respectively.

To estimate NoV-associated deaths and hospitalizations among children in developing countries, we multiplied global estimates of diarrhea deaths ([@R1]) and hospitalizations ([@R9]) by the pooled proportion of NoV among children \<5 years of age hospitalized with diarrhea. Data from developing countries were sparse on fraction of NoV-associated diarrhea episodes in the outpatient setting.

Results
=======

Overall, we reviewed 235 studies and identified 31 original studies that met our inclusion criteria ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}) ([@R6],[@R12]--[@R41]). Of these 31 studies, 20 were conducted in high-income countries, 2 were high-middle-income countries, 5 were low-middle income, and 4 were low-income countries, based on World Bank classification of economies. The duration of these studies was 1--5 years. Fourteen studies tested only for NoV ([@R13],[@R14],[@R19],[@R21],[@R22],[@R27],[@R29],[@R30],[@R35],[@R37]--[@R41]); 17 tested for NoV and sapovirus ([@R6],[@R12],[@R15]--[@R18],[@R20],[@R23]--[@R26],[@R28],[@R31]--[@R34],[@R36]). Among 13 of 17 studies that tested for and presented separate detection rates on both caliciviruses, NoV was detected in 84.5% and 88.5% of the community- and hospital-based studies, respectively ([@R6],[@R15],[@R16],[@R20],[@R23]--[@R26],[@R31]--[@R34],[@R36]). In these 13 studies, 69%--90% of the outpatient cases and 61%--100% of the hospital cases with caliciviruses were identified as NoV.

###### Summary of studies examining prevalence of NoV in persons with severe sporadic AGE, using RT-PCR for studies \>12 months' duration, community and outpatient clinics\*

  Ref            Country       Study duration, mos   Age group, y   No. AGE cases   No. NoV positive (single and mixed)   \% NoV positive   No. mixed pathogens   \% Mixed pathogens   No. control patients   \% Control patients positive for NoV
  -------------- ------------- --------------------- -------------- --------------- ------------------------------------- ----------------- --------------------- -------------------- ---------------------- --------------------------------------
  ([@R6])†       England       12†                   All            2,422           871                                   36.0              --‡                   --                   2,205                  16.2
  ([@R12])§      France        26                    \<13           414             49                                    11.8              27                    6.5                  50                     0.0
  ([@R15])       Netherlands   12                    All            709             114                                   16.1              --                    --                   669                    5.2
  ([@R16])       Netherlands   36                    All            857             43                                    5.0               --                    --                   574                    1.0
  ([@R13])*¶*    Hong Kong     12                    All            995             92                                    9.2               --                    --                   --                     --
  ([@R14])       Australia     17                    All            638             73                                    11.4              7                     1.1                  --                     --
  ([@R33])*¶*    India         36                    \<5            500             38                                    7.6               5                     1.0                  173                    4.0
  ([@R18])§*¶*   Chile         31                    \<5            274             15                                    5.5               --                    --                   --                     --
  ([@R17])§      Finland       21                    \<2            1,477           264                                   17.8              13                    0.9                  47                     0.0
  ([@R20])       Japan         12                    \<11           557             106                                   19.0              12                    2.2                  --                     --
  ([@R21])       Japan         12                    \<11           402             58                                    14.4              --                    --                   --                     --
  ([@R19])       Japan         12                    \<5            752             139                                   18.5              3                     0.4                  --                     --
  ([@R34])¶\#    Tunisia       15                    \<12           380             49                                    12.9              13                    3.4                  --                     --

\*NoV, norovirus; AGE, acute gastroenteritis; RT-PCR, reverse transcription--PCR; Ref, reference; --. not assessed in the study. Studies were of \>12 months' duration. †Using RT-PCR, tested stored specimens from a previous study that used electron microscopy for NoV detection; enrollment was staggered over 29 months with 70 clinics, each enrolling patients for 12 months. ‡Tested for mixed pathogens but did not provide pathogen-specific results. §NoV prevalance in these studies was estimated by multiplying the calicivirus prevalance by average proportion of caliciviruses determined to be NoV (84.5%) among outpatient studies reporting NoV and sapovirus results separately. ¶O'Ryan et al. ([@R18]) included clinic-, emergency department--, and hospital-based patients; Lau et al. ([@R13]), Monica et al. ([@R33]), and Sdiri-Loulizi et al. ([@R34]) included community/clinic- and hospital-based patients. Only community and clinic data are presented here. \#Age- and setting-specific data were obtained through personal communication with the author.

###### Summary of studies that examined prevalence of NoV in persons with severe sporadic AGE, emergency department visits and hospitalizations, by using RT-PCR for \>12 months\*

  Ref                    Country        Study duration, mo   Age group, y   No. AGE cases   No. NoV positive (single and mixed)   \% NoV positive   No. NoV positive (mixed)   \% Mixed   No. control patients   \% Controls positive for NoV
  ---------------------- -------------- -------------------- -------------- --------------- ------------------------------------- ----------------- -------------------------- ---------- ---------------------- ------------------------------
  Emergency department                                                                                                                                                                                           
  ([@R22])               Spain          12                   \<14           363             16                                    4.4               1                          0.3        --                     --
  ([@R18])†‡             Chile          25 and 17§           \<5            248             23                                    9.3               --                         --         80                     1.3
  Hospital                                                                                                                                                                                                       
  ([@R35])               Italy          12                   \<3            365             93                                    25.5              35                         9.6        --                     --
  ([@R23])               Malawi         12                   \<5            398             26                                    6.5               12                         3.0        --                     --
  ([@R24])               Vietnam        12                   \<15           1,339           72                                    5.4               0                          0.0        --                     --
  ([@R25])               Thailand       12                   \<5            105             8                                     7.6               --                         --         --                     --
  ([@R36])               Thailand       20                   \<5            248             35                                    14.1              --                         --         --                     --
  ([@R26])               Australia      60                   \<5            1,233           108                                   8.8               --                         --         --                     --
  ([@R13])‡              Hong Kong      12                   All            735             123                                   16.7              --                         --         --                     --
  ([@R37])               South Korea    24                   \<5            962             132                                   13.7              18                         1.9        --                     --
  ([@R33])‡              India          36                   \<5            350             53                                    15.1              26                         7.4        173                    4.0
  ([@R27])               Germany        12                   \<16¶          217             45                                    20.7              --                         --         50                     4.0
  ([@R38])               Japan          24                   Children       500             66                                    13.2              2                          0.4        --                     --
  ([@R18])‡              Chile          25 and 17§           \<5            162             8                                     4.9               --                         --         50                     0.0
  ([@R39])               Madagascar     13                   \<5            237             14                                    5.9               0                          0.0        --                     --
  ([@R27])†              Peru           24                   \<5            233             72                                    30.7              56                         23.9       248                    11.4
  ([@R29])               Spain          12                   \<5            656             79                                    12.0              36                         5.5        --                     --
  ([@R30])               Australia      36                   \<5            360             9                                     2.5               --                         --         --                     --
  ([@R34])‡\#            Tunisia        27                   \<12           252             61                                    24.2              12                         4.8        --                     --
  ([@R40])               Brazil         12                   \<5            318             65                                    20.4              14                         4.4        --                     --
  ([@R31])               South Africa   48                   All            1,296           32                                    2.5               --                         --         --                     --
  ([@R41])               South Korea    12                   \<5            762             114                                   15.0              --                         --         --                     --
  ([@R31])               USA            24                   \<4            1,840           131                                   7.1               --                         --                                --

\*NoV, norovirus; AGE, acute gastroenteritis; RT-PCR, reverse transcription--PCR; Ref, reference; --, not assessed in the study. †NoV prevalence (total and mixed alone) in these studies was estimated by multiplying the calicivirus prevalence by average proportion fo caliciviruses determined to be NoV (88.5%) among hospital-based studies reporting NoV and sapovirus results separately. ‡O'Ryan et al. ([@R18]) included clinic-, emergency department--, and hospital-based patients; Lau et al. ([@R13]), Monica et al. ([@R33]), and Sdiri-Loulizi et al. ([@R34]) included community/clinic- and hospital-based patients. Only emergency department and hospitalization data are presented here. §Included 2 hospitals with 25- and 17-month enrollment periods. ¶98% (213 of 217) of the case-patients were \<5 y of age. \#Age- and setting-specific data were obtained through personal communication with the author.

Illness by Age and Setting
--------------------------

### Community- or Clinic-based Cases (i.e., Mild and Moderate Diarrhea)

Among the 13 studies of community- or clinic-based diarrhea cases, NoVs were detected in 5%--36% of cases; pooled proportion was 12% (95% CI 9%--15%; Cochran Q 335; df 12) ([Figure 1](#F1){ref-type="fig"}). Five studies enrolled both adults and children, and 8 studies focused only on children, each with varying age ranges (overall range 0--13 years). In the 8 studies that assessed mixed infections, 0.4%--6.5% (median 1.1%) of the gastroenteritis cases were also positive for another viral or bacterial pathogen ([Table 1](#T1){ref-type="table"}).

![Summary of studies assessing proportion of norovirus (NoV)-positive fecal samples among persons with community and outpatient cases of sporadic diarrhea (all ages). \*Lau et al. ([@R13]), O'Ryan et al. ([@R18]), Monica et al. ([@R33]), and Sdiri-Loulizi et al. ([@R34]) included outpatient and emergency department/hospital patients, but only outpatient data are included in this figure. †Pooled proportion calculated by using the random effects model (DerSimonian and Laird method, StatsDirect Ltd, Cheshire, UK). For studies that included controls, prevalence of NoV among controls was subtracted from prevalence of NoV among case-patients. CI, confidence interval.](07-1114-F1){#F1}

### Hospitalizations (i.e., Severe Diarrhea)

Twenty-three studies \[hospital-based (n = 21); emergency department--based (n = 1); both (n = 1)\] evaluated NoV disease among hospitalized diarrhea case-patients in whom the proportion of NoV disease ranged from 3% to 31%; pooled proportion was 11% (95% CI 8%--14%). Most (n = 19) of these studies of severe diarrhea cases focused on children \<5 years of age, and the pooled proportion of NoV disease in these studies was 12% (95% CI 10%--15%) ([Figure 2](#F2){ref-type="fig"}). In the 5 studies that assessed for multiple enteric pathogens, mixed infections were detected in 0%--24% (median 3.7%) of the gastroenteritis cases ([Table 2](#T2){ref-type="table"}).

![Summary of studies assessing proportion of norovirus (NoV)-positive fecal samples among hospitalized and emergency department cases of children \<5 years of age who had sporadic diarrhea. \*Lau et al. ([@R13]), O'Ryan et al. ([@R18]), Monica et al. ([@R33]), and Sdiri-Loulizi et al. ([@R34]) included outpatient and emergency department/hospital patients, but only inpatient data are included in this figure. †Oh et al. ([@R27]), 98% (213 of 217) of the case-patients were \<5 years of age. ‡Pooled proportion calculated using the random effects model (DerSimonian and Laird method (StatsDirect Ltd, Cheshire, UK). For studies that included controls, prevalence of NoV among controls was subtracted from prevalence of NoV among case-patients. CI, confidence interval.](07-1114-F2){#F2}

Most (\>95%) of the world's diarrheal deaths occur in low-middle-- and low-income countries. In our review, 7 of 19 studies assessing prevalence of severe NoV disease among children \<5 years of age were conducted in these countries ([@R23],[@R25],[@R28],[@R33],[@R34],[@R36],[@R39]). Pooled proportions for NoV-associated childhood hospitalization were 12% (95%CI 8%--17%) among low-middle and low income in comparison to 12% (95% CI 9%--16%) for high- and high-middle--income countries.

Studies with Concurrent Controls
--------------------------------

Concurrent diarrhea-free controls were enrolled in 9 of 31 studies, and NoVs were detected in 0%--16% (median 4%) of the controls ([@R6],[@R12],[@R15]--[@R18],[@R27],[@R28],[@R33]). On the basis of the difference in detection rate between cases and controls in these studies, we estimate that the fraction of cases attributable to NoV in these studies was 4%--20% (median 12%) for mild to moderate diarrhea and 2%--26% (median 11%) for severe diarrhea.

Strain Characterization
-----------------------

Overall, 19 studies characterized the NoV strains by using nucleotide sequencing ([@R13],[@R14],[@R17],[@R19]--[@R21],[@R23],[@R24],[@R26],[@R27],[@R32]--[@R36],[@R38]--[@R41]). Among NoV cases, strains belonging to NoV genogroup (G) II were the most common (range 75%--100%). With the exception of 2 studies, the overwhelming majority of the NoV strains belonged to the GII.4 cluster ([@R21],[@R23]). In Malawi (1 of the 4 low-income countries in our analysis), GII.3 strains were detected in 69% of the samples that were sequenced ([@R23]). Similarly, in 2006, novel GII.3 strains were identified in 44% of the samples in a clinic-based study in Japan ([@R21]). Through genetic characterization, the authors demonstrated that these GII.3 strains likely were recombinant strains that appeared over a period of 4 months.

Estimated Prevalence of NoV Disease in Children
-----------------------------------------------

We estimate that each year NoVs cause ≈900,000 episodes of gastroenteritis that require a clinic visit and ≈64,000 hospitalizations among children \<5 years of age residing in high-income countries ([Table 3](#T3){ref-type="table"}). If one assumes that the proportion of annual childhood diarrhea-associated hospitalizations (≈124 million) and deaths (≈1.8 million) in developing countries approximates the overall proportion of children (12.1%) with severe NoV illness in our review, NoVs may cause up to 1.1 million hospitalizations and 218,000 deaths each year in children in developing countries.

###### Estimates of annual number of episodes of norovirus-associated diarrhea among children \<5 years of age in industrialized and developing countries, by setting

  Setting                     Annual no. diarrhea-associated events\*   Pooled proportion of episodes attributable to noroviruses, %   Total no. norovirus episodes   Annual incidence per 100,000 children†‡
  --------------------------- ----------------------------------------- -------------------------------------------------------------- ------------------------------ -----------------------------------------
  Industrialized countries†                                                                                                                                           
  Outpatient                  7,743,000                                 11.7                                                           906,000                        1,665
  Inpatient                   531,000                                   12.1                                                           64,200                         118
  Developing countries‡§                                                                                                                                              
  Inpatient                   9,015,000                                 12.1                                                           1,091,000                      197
  Deaths                      1,800,000                                 12.1                                                           218,000                        39

\*Refer to Methods section of article. †Industrialized countries' incidence based on UNICEF 2003 population estimates of 54,425,000 children \<5 y of age in developing countries ([www.unicef.org/sowc05/english/Developingregional.html](http://www.unicef.org/sowc05/english/Developingregional.html)). ‡Developing countries' incidence based on UNICEF 2003 population estimates of 552,742,000 children \<5 y of age in industrialized ([www.unicef.org/sowc05/english/Industrializedregional.html](http://www.unicef.org/sowc05/english/Industrializedregional.html)) §Data from developing countries were sparse on fraction of norovirus-associated diarrhea episodes in the outpatient setting.

Discussion
==========

This systematic review of studies that used RT-PCR for detection of NoVs in fecal specimens clearly indicates that these viruses play an important role in the cause of both mild and severe gastroenteritis worldwide. In 1979, Greenberg et al. demonstrated that virtually all children in various countries worldwide acquired antibodies to NoVs by 5--15 years of age ([Technical Appendix 2](#SD2){ref-type="local-data"}). However, despite strong evidence that NoV infection was ubiquitous, detection rates in children hospitalized with diarrhea were low in early studies that used electron microscopy and antigen assays ([@R4]). The advent of conventional RT-PCR for the diagnosis of NoVs has substantially changed our understanding of their epidemiology. Among all reported studies that used conventional RT-PCR, NoVs were detected in ≈12% of children \<5 years of age with severe diarrhea, which suggests that these viruses are the second most common cause of severe childhood gastroenteritis, following rotavirus. In addition, although some studies suggest that NoV infections in the community are slightly less severe than rotavirus infections, data also exist to suggest that these childhood infections may be similar in severity, which may particularly apply to hospitalized children ([Technical Appendix 2](#SD2){ref-type="local-data"}). On the basis of the pooled detection rates of NoV in our review, we would estimate that in the United States alone NoVs may account for \>235,000 clinic visits, 91,000 emergency room visits, and 23,000 hospitalizations among children \<5 years of age ([@R10]). Limited data from developing countries are available to make firm estimates, but NoV disease may cause \>1 million hospitalizations and 200,000 deaths each year among children \<5 years of age.

Although these figures provide a preliminary indication of the substantial magnitude of illness from NoV disease, they may underestimate the true extent of disease. Evidence suggests that detection of NoVs in fecal specimens by conventional RT-PCRs may be limited by factors such as low virus concentrations in feces, improper specimen storage, inefficient viral RNA extraction, presence of fecal reverse transcriptase inhibitors, and use of different primers ([Technical Appendix 2](#SD2){ref-type="local-data"}). In addition, NoVs are extremely genetically diverse and none of the reported conventional RT-PCR assays is able to detect all strains ([Technical Appendix 2](#SD2){ref-type="local-data"}). These hypotheses are supported by the findings of an evaluation of children with gastroenteritis in Peru in which both RT-PCR testing of fecal specimens and serologic assays were used to assess NoV infection, and serologic testing was found to increase the rates of NoV detection from 35% with fecal testing alone to 55% by use of either assay ([@R28]). A recent validation study comparing state-of-the-art real-time RT-PCR with conventional RT-PCR found that the sensitivity of real-time RT-PCR was greater than that of the conventional method, especially for samples containing low NoV concentrations or RT-PCR inhibitors ([Technical Appendix 2](#SD2){ref-type="local-data"}). The broader application of real-time RT-PCR assays to diagnose NoV among children hospitalized with gastroenteritis should provide better estimates of the true prevalence of disease.

Some factors could have led us to overestimate the extent of sporadic NoV disease. Our estimates of sporadic NoV disease prevalence are based on a review of active surveillance data of all diarrhea cases and do not exclude cases originating from an outbreak. In a few studies, NoVs were detected in patients who were co-infected with another pathogen, and only a limited number of studies enrolled concurrent healthy controls, thus making it difficult to determine the fraction of diarrhea cases truly attributable to NoV. Among all studies testing for co-infections, however, the median rate of detecting another pathogen in addition to NoV was low (2%). This finding, combined with the fact that most studies only assessed for NoV among samples that previously tested negative for other bacterial and viral pathogens, suggests that our overall pooled proportion attributable to NoVs is unlikely to be much lower. In addition, for the studies that enrolled diarrhea-free controls, we subtracted control prevalence from the case prevalence of NoV disease when calculating the overall pooled estimate. Lastly, other unmeasured factors underestimating disease prevalence that could not be accounted for, such as inefficient primers, low virus shedding, delays in specimen collection, and lack of a sensitive case-definition are also likely to exist in these studies.

The heterogeneity in the NoV literature is evident and should be considered when interpreting the results of this review. Our systematic approach and strict inclusion criteria likely reduced heterogeneity but do not eliminate biases in the original studies, diversity in study design and population, and publication bias. Nonetheless, the findings of this review suggest that NoVs are a frequent cause of mild and severe sporadic gastroenteritis among children in high- and middle-income countries. In addition, hospital studies in our review only assessed patients admitted with diarrhea. Because of the highly infectious nature of NoVs, substantial additional health and economic effects would also occur from nosocomial disease and outbreaks in healthcare facilities, as previously identified by Lopman et al ([@R7]). NoVs are also a frequent cause of severe illness and death from diarrhea among children in developing countries, although firm conclusions cannot be made because of limited data. Systematic evaluations that use broadly reactive, state-of-the-art diagnostic assays, with concurrent evaluation of healthy controls and examination of potential co-infection, are needed to fully understand the role of NoVs in the etiology of sporadic childhood gastroenteritis. These evaluations are especially necessary in developing countries, where diarrhea remains a leading cause of childhood death, causing \>1.8 million annual deaths ([@R1]).

The increasing evidence documenting the magnitude of the NoV disease prevalence provides support for considering targeted interventions, such as vaccines, for reducing the extent of this illness among young children. However, if one considers that NoV frequently causes both sporadic and epidemic gastroenteritis and can affect all age groups, some other potential targets for vaccination may include elderly persons in nursing homes, who are vulnerable to severe complications, and military recruits, in whom sporadic and epidemic NoV disease is known to incur substantial illness and financial costs from work disruption ([@R7]; [Technical Appendix 2](#SD2){ref-type="local-data"}). The development of vaccines against NoVs will likely be challenging because the immunity to these viruses and the diversity and evolution of circulating strains are incompletely understood ([Technical Appendix 2](#SD2){ref-type="local-data"}). However, genotype II, cluster 4 NoV strains appeared to be by far the most prevalent strains among the studies we reviewed, and these strains may be the primary targets for vaccine development.

Carefully designed epidemiologic studies that evaluate NoV prevalence in children with diarrhea and a suitable comparison group and that use sensitive molecular assays will help further define target groups that would benefit from vaccines and other interventions. A particularly pressing need exists for better quantifying the extent of severe norovirus disease among children in developing countries and identifying prevention strategies to help reduce the prevalence of deaths from diarrhea in the poorest countries.
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